These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 19572312

  • 1. Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL.
    Bradbury BD, Do TP, Winkelmayer WC, Critchlow CW, Brookhart MA.
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):932-40. PubMed ID: 19572312
    [Abstract] [Full Text] [Related]

  • 2. Exploring relative mortality and epoetin alfa dose among hemodialysis patients.
    Bradbury BD, Wang O, Critchlow CW, Rothman KJ, Heagerty P, Keen M, Acquavella JF.
    Am J Kidney Dis; 2008 Jan; 51(1):62-70. PubMed ID: 18155534
    [Abstract] [Full Text] [Related]

  • 3. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N, Sriuranpong V, Suwanrusme H.
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [Abstract] [Full Text] [Related]

  • 4. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R, Epoetin Zeta Study Group.
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [Abstract] [Full Text] [Related]

  • 5. Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients.
    Bradbury BD, Critchlow CW, Weir MR, Stewart R, Krishnan M, Hakim RH.
    Nephrol Dial Transplant; 2009 Mar; 24(3):919-25. PubMed ID: 18840893
    [Abstract] [Full Text] [Related]

  • 6. Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization.
    Servilla KS, Singh AK, Hunt WC, Harford AM, Miskulin D, Meyer KB, Bedrick EJ, Rohrscheib MR, Tzamaloukas AH, Johnson HK, Zager PG.
    Am J Kidney Dis; 2009 Sep; 54(3):498-510. PubMed ID: 19628315
    [Abstract] [Full Text] [Related]

  • 7. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.
    Savonije JH, van Groeningen CJ, Wormhoudt LW, Giaccone G.
    Oncologist; 2006 Feb; 11(2):206-16. PubMed ID: 16476841
    [Abstract] [Full Text] [Related]

  • 8. Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: an integrated analysis of the Canadian experience.
    Quirt I, Kovacs M, Couture F, Turner AR, Noble M, Burkes R, Dolan S, Plante RK, Lau CY, Chang J.
    Oncologist; 2006 Jan; 11(1):73-82. PubMed ID: 16401716
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U, Ba16285 Study Investigators.
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [Abstract] [Full Text] [Related]

  • 10. Comparison of two epoetin brands in anemic hemodialysis patients: results of two efficacy trials and a single-dose pharmacokinetic study.
    Milutinović S, Plavljanić E, Trkulja V.
    Fundam Clin Pharmacol; 2006 Oct; 20(5):493-502. PubMed ID: 16968421
    [Abstract] [Full Text] [Related]

  • 11. Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients.
    Weinhandl ED, Gilbertson DT, Collins AJ.
    Am J Nephrol; 2011 Oct; 34(4):298-308. PubMed ID: 21829009
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis.
    Haag-Weber M, Vetter A, Thyroff-Friesinger U, INJ-Study Group.
    Clin Nephrol; 2009 Nov; 72(5):380-90. PubMed ID: 19863881
    [Abstract] [Full Text] [Related]

  • 13. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
    Collins AJ, Brenner RM, Ofman JJ, Chi EM, Stuccio-White N, Krishnan M, Solid C, Ofsthun NJ, Lazarus JM.
    Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210
    [Abstract] [Full Text] [Related]

  • 14. Dose of epoetin alfa used in haemodialysis patients when switching from subcutaneous to intravenous administration.
    Pussell BA, Walker R.
    Nephrology (Carlton); 2007 Apr; 12(2):120-5. PubMed ID: 17371332
    [Abstract] [Full Text] [Related]

  • 15. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.
    Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E.
    J Clin Oncol; 2005 Sep 01; 23(25):5960-72. PubMed ID: 16087945
    [Abstract] [Full Text] [Related]

  • 16. Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia.
    Henry DH, Gordan LN, Charu V, Wilhelm FE, Williams D, Xie J, Woodman RC.
    Curr Med Res Opin; 2006 Jul 01; 22(7):1403-13. PubMed ID: 16834839
    [Abstract] [Full Text] [Related]

  • 17. Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL.
    Bradbury BD, Danese MD, Gleeson M, Critchlow CW.
    Clin J Am Soc Nephrol; 2009 Mar 01; 4(3):630-7. PubMed ID: 19261826
    [Abstract] [Full Text] [Related]

  • 18. Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia.
    Piccoli A, Malagoli A, Komninos G, Pastori G.
    J Nephrol; 2002 Mar 01; 15(5):565-74. PubMed ID: 12455725
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients.
    Locatelli F, Villa G, Messa P, Filippini A, Cannella G, De Ferrari G, Naso A, Rossi E, Formica M, Lombardi L, Rotolo U, Conte F.
    J Nephrol; 2008 Mar 01; 21(3):412-20. PubMed ID: 18587731
    [Abstract] [Full Text] [Related]

  • 20. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial.
    Macdougall IC, Temple RM, Kwan JT.
    Nephrol Dial Transplant; 2007 Mar 01; 22(3):784-93. PubMed ID: 16968726
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.